Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1971 1
1977 1
1978 3
1980 1
1982 1
1985 2
1986 1
1987 2
1988 7
1989 4
1990 9
1991 7
1992 14
1993 9
1994 15
1995 15
1996 16
1997 18
1998 34
1999 34
2000 46
2001 61
2002 88
2003 88
2004 124
2005 142
2006 163
2007 181
2008 238
2009 210
2010 250
2011 285
2012 331
2013 345
2014 328
2015 294
2016 352
2017 335
2018 385
2019 400
2020 410
2021 400
2022 381
2023 342
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

5,639 results

Results by year

Filters applied: . Clear all
Page 1
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial.
Shitara K, Lordick F, Bang YJ, Enzinger P, Ilson D, Shah MA, Van Cutsem E, Xu RH, Aprile G, Xu J, Chao J, Pazo-Cid R, Kang YK, Yang J, Moran D, Bhattacharya P, Arozullah A, Park JW, Oh M, Ajani JA. Shitara K, et al. Among authors: park jw. Lancet. 2023 May 20;401(10389):1655-1668. doi: 10.1016/S0140-6736(23)00620-7. Epub 2023 Apr 15. Lancet. 2023. PMID: 37068504 Clinical Trial.
Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial.
Shah MA, Shitara K, Ajani JA, Bang YJ, Enzinger P, Ilson D, Lordick F, Van Cutsem E, Gallego Plazas J, Huang J, Shen L, Oh SC, Sunpaweravong P, Soo Hoo HF, Turk HM, Oh M, Park JW, Moran D, Bhattacharya P, Arozullah A, Xu RH. Shah MA, et al. Among authors: park jw. Nat Med. 2023 Aug;29(8):2133-2141. doi: 10.1038/s41591-023-02465-7. Epub 2023 Jul 31. Nat Med. 2023. PMID: 37524953 Free PMC article. Clinical Trial.
Widespread somatic L1 retrotransposition in normal colorectal epithelium.
Nam CH, Youk J, Kim JY, Lim J, Park JW, Oh SA, Lee HJ, Park JW, Won H, Lee Y, Jeong SY, Lee DS, Oh JW, Han J, Lee J, Kwon HW, Kim MJ, Ju YS. Nam CH, et al. Among authors: park jw. Nature. 2023 May;617(7961):540-547. doi: 10.1038/s41586-023-06046-z. Epub 2023 May 10. Nature. 2023. PMID: 37165195 Free PMC article.
Tcf7l2 in hepatocytes regulates de novo lipogenesis in diet-induced non-alcoholic fatty liver disease in mice.
Lee DS, An TH, Kim H, Jung E, Kim G, Oh SY, Kim JS, Chun HJ, Jung J, Lee EW, Han BS, Han DH, Lee YH, Han TS, Hur K, Lee CH, Kim DS, Kim WK, Park JW, Koo SH, Seong JK, Lee SC, Kim H, Bae KH, Oh KJ. Lee DS, et al. Among authors: park jw. Diabetologia. 2023 May;66(5):931-954. doi: 10.1007/s00125-023-05878-8. Epub 2023 Feb 10. Diabetologia. 2023. PMID: 36759348 Free PMC article.
Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Cheng AL, Vogel A, Tovoli F, Ueshima K, Aikata H, López CL, Pracht M, Meng Z, Daniele B, Park JW, Palmer D, Tamai T, Saito K, Dutcus CE, Lencioni R. Kudo M, et al. Among authors: park jw. J Hepatol. 2023 Jan;78(1):133-141. doi: 10.1016/j.jhep.2022.09.006. Epub 2022 Sep 20. J Hepatol. 2023. PMID: 36341767 Free article. Clinical Trial.
ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma.
Klempner SJ, Lee KW, Shitara K, Metges JP, Lonardi S, Ilson DH, Fazio N, Kim TY, Bai LY, Moran D, Yang J, Arozullah A, Park JW, Raizer JJ, Bang YJ, Shah MA. Klempner SJ, et al. Among authors: park jw. Clin Cancer Res. 2023 Oct 2;29(19):3882-3891. doi: 10.1158/1078-0432.CCR-23-0204. Clin Cancer Res. 2023. PMID: 37490286 Free PMC article. Clinical Trial.
KAAACI Guidelines for Allergen Immunotherapy.
Lee HY, Lee SM, Kang SY, Kim K, Kim JH, Ryu G, Min JY, Park KH, Park SY, Sung M, Lee Y, Yang EA, Jee HM, Ha EK, Shin YS, Chung EH, Choi SH, Koh YI, Kim ST, Nahm DH, Park JW, Shim JY, An YM, Han DH, Han MY, Lee YW, Choi JH; Korean Academy of Asthma Allergy and Clinical Immunology (KAAACI) Allergen Immunotherapy and Allergen Working Group. Lee HY, et al. Among authors: park jw. Allergy Asthma Immunol Res. 2023 Nov;15(6):725-756. doi: 10.4168/aair.2023.15.6.725. Allergy Asthma Immunol Res. 2023. PMID: 37957792 Free PMC article. Review.
Updating Osteonecrosis of the Femoral Head.
Ko YS, Ha JH, Park JW, Lee YK, Kim TY, Koo KH. Ko YS, et al. Among authors: park jw. Hip Pelvis. 2023 Sep;35(3):147-156. doi: 10.5371/hp.2023.35.3.147. Epub 2023 Sep 6. Hip Pelvis. 2023. PMID: 37727298 Free PMC article. Review.
5,639 results